This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio
by Zacks Equity Research
Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
The Zacks Analyst Blog Highlights: Community Health Systems, Mednax, HCA Healthcare and Tenet Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Community Health Systems, Mednax, HCA Healthcare and Tenet Healthcare
3 Hospital Stocks That Crushed S&P 500 YTD, Set to Rise Further
by Srijita Guha
High patient volumes, mergers and buyouts, and demand for virtual health services are likely to help hospital companies like THC, HCA and CYH.
MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.
Mednax (MD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 9.52% and 2.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
by Srijita Guha
Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.
Why Mednax (MD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What's in Store for Universal Health's (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q3 earnings are likely to have suffered elevated costs, partly offset by better patient volumes.
Centene (CNC) Gears Up for Q3 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect better revenues and membership growth.
Mednax (MD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Increase Y/Y
by Zacks Equity Research
Anthem's (ANTM) third-quarter results reflect higher revenues and solid contribution from its segments.
What's in Store for HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to reflect better revenues owing to higher patient volumes.
NextGen's (NXGN) Integrated Platform Gets Leveraged by Mednax
by Zacks Equity Research
Mednax utilizes NextGen's (NXGN) fully-integrated platform to enhance its efficacy in placing crucial information on patients' health and well-being at the physician's fingertips.
Mednax (MD) Invests in Brave Care to Boost Pediatric Business
by Zacks Equity Research
Mednax (MD) and Brave Care form a relationship to provide enhanced pediatric care and pursue its pipeline of pediatric clinics' plan.
Here's Why You Should Retain MEDNAX (MD) in Your Portfolio
by Zacks Equity Research
Riding high on its revenue stream and strategic measures, MEDNAX (MD) holds potential to reap benefits for investors.
MEDNAX's (MD) Earnings Beat Estimates in Q2, Improve Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q2 results reflect solid volumes, partly offset by escalating expenses.
Mednax (MD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 24.24% and 3.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Humana's (HUM) second-quarter earnings results to reflect a steep expense level, partly offset by better revenues.
HCA Healthcare's (HCA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 earnings gain traction from higher revenues and improved admissions.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to have gained from better revenues.
Down 11.6% in 4 Weeks, Here's Why Mednax (MD) Looks Ripe for a Turnaround
by Zacks Equity Research
Mednax (MD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
UnitedHealth (UNH) Beats on Q2 Earnings, Hikes '21 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter 2021 results reflect improving revenues resulting in top-line growth at both the business units, partly offset by higher costs.
Why Should You Hold HCA Healthcare (HCA) in Your Portfolio?
by Zacks Equity Research
Riding high on growth measures and a solid 2021 guidance, HCA Healthcare (HCA) holds enough potential to reap benefits for investors.